Almost 2 Years Ago
1 Min Read

Off goes CLVS. The stock dipped today. Here's what's moving the stock:



Clovis Oncology Inc (CLVS) is trading -6% lower at $1.4 today. The Health Care sector is having a generally mildly bullish day, this hasn't really affected the stock's share price, as it faltering behind other names in the space.

  • Clovis has filed for US and EU approval of Rubraca as an initial maintenance drug for ovarian cancer.

Clovis Oncology Inc has been trading between a 52-week high of $4.91 and a 52-week low of $0.581. The stock has a market cap of $202 Million.

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

Headlines


What Is Going on With Clovis Oncology (CLVS) Stock Today?
InvestorPlace 09-13-22

Clovis files for US, EU approval of Rubraca as initial maintenance drug for ovarian cancer
Seeking Alpha 09-13-22

Clovis Oncology, Inc.: Clovis Oncology Submits Applications for Rubraca Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
Finanz Nachrichten 09-13-22

BUSINESS WIRE: Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
Finanztreff 09-13-22

Clovis Oncology Submits Applications for Rubraca Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
Wallstreet:Online 09-13-22